Tandutinib, Free Base (4-[6-methoxy-7-[3-(1-piperidinyl)propoxy]-4-quinazolinyl]-N-[4-(1-methylethoxy)phenyl]-1-piperazinecarboxamide, MLN518, CT53518, D06005)

Tandutinib (also known as MLN518 or CT53518) is an orally active inhibitor of Fms-like tyrosine kinase 3 (FLT3) kinase, PDGFRb and c-Kit. It inhibits FLT3 phosphorylation, downstream signaling and tumor growth in vitro and in animal models.\n\nSolubility:\nSoluble in DMSO at 25mg/ml with slight warming; soluble in ethanol at 25mg/ml with slight warming; very poorly soluble in water; maximum solubility in plain water is estimated to be about 50-100uM; buffers, serum, or other additives may increase or decrease the aqueous solubility.\n\nStorage and Stability:\nMay be stored at RT for short-term only. Long-term storage is recommended at -20 degrees C. For maximum recovery of product, centrifuge the original vial prior to removing the cap.

Prices direct from United States Biological

Quick response times

Exclusive Biosave savings/discounts

SPECIFICATIONS

Catalog Number

T0895-50

Size

25mg

Form

Supplied as a white to off-white powder.

Purity

~99%

References

1. Cheng, Y. and Paz, K. \"Tandutinib, an oral, small-molecule inhibitor of FLT3 for the treatment of AML and other cancer indications.\" IDrugs 11:46-56 (2008). 2. Walters, D.K., et al. \"RNAi-induced down-regulation of FLT3 expression in AML cell lines increases sensitivity to MLN518.\" Blood 105:2952-2954 (2005). 3. Kelly, L.M., et al. \"CT53518, a novel selective FLT3 antagonist for the treatment of acute myelogenous leukemia (AML).\" Cancer Cell 1:421-432 (2002). 4. Griswold, I.J., et al. \"Effects of MLN518, a dual FLT3 and KIT inhibitor, on normal and malignant hematopoiesis.\" Blood 104:2912-2918 (2004). 5. Clark, J.J., et al. \"Variable sensitivity of FLT3 activation loop mutations to the small molecule tyrosine kinase inhibitor MLN518.\" Blood 104:2867-2872 (2004).